CN114073687A - Application of cannabidiol in preparation of medicine for preventing and treating acne rosacea - Google Patents
Application of cannabidiol in preparation of medicine for preventing and treating acne rosacea Download PDFInfo
- Publication number
- CN114073687A CN114073687A CN202110969262.9A CN202110969262A CN114073687A CN 114073687 A CN114073687 A CN 114073687A CN 202110969262 A CN202110969262 A CN 202110969262A CN 114073687 A CN114073687 A CN 114073687A
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- medicament
- rosacea
- medicine
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 35
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 31
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 201000004700 rosacea Diseases 0.000 title claims abstract description 30
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 13
- 206010015150 Erythema Diseases 0.000 claims abstract description 17
- 241001303601 Rosacea Species 0.000 claims abstract description 16
- 231100000321 erythema Toxicity 0.000 claims abstract description 16
- 206010043189 Telangiectasia Diseases 0.000 claims abstract description 13
- 208000009056 telangiectasis Diseases 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims abstract description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010058679 Skin oedema Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 abstract description 4
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 11
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an application of cannabidiol in preparing a medicine for preventing and treating acne rosacea. Also discloses a medicament for preventing and/or treating acne rosacea, which is prepared by using cannabidiol as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. The cannabidiol can effectively improve erythema and edema, improve telangiectasia, reduce inflammation and prevent and/or treat rosacea, and provides a new clinical choice.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to application of cannabidiol in preparation of a medicine for preventing and treating acne rosacea.
Background
Rosacea is a chronic inflammatory dermatosis mainly occurring in erythema and telangiectasia of face center, dry desquamation and seborrhea appear on face in early stage, there are symmetrically distributed erythema, capillary vessel further dilates in middle and later stage, hair follicle enlarges, acne-like papule and nasal nodule appear, and eye inflammation such as conjunctivitis, keratitis, etc. can be caused when the eye inflammation is serious.
Rosacea is a multifactorial disease whose causes include: the phenomena of dilated face capillaries, damaged skin barrier, dry desquamation and hypersecretion of sebum and formation of erythema caused by stimulating diet, strenuous exercise, high temperature, cold, light and wind; chronic skin inflammation and nerve immunity abnormality caused by improper use of skin care products, environmental pollution, irregular long-term work and rest, bad life habits and other factors; skin barrier damage and natural immune function abnormality caused by microorganism invasion of demodex and the like and skin microecological imbalance, and the phenomena of dryness, desquamation and excessive sebum secretion occur to generate inflammation; or skin thinning and increased telangiectasia due to topical long term use of corticosteroid hormones.
Clinically, the rosacea is divided into the following 4 main types according to different parts, different periods and different skin damage characteristics, different types can be mutually overlapped, and partial types can be mutually converted.
(1) Erythema telangiectasia type: most of the hair is firstly sent to the cheek part, and the few hair is firstly sent to the nose or the periphery of the mouth; showing paroxysmal flushing of the cheek, aggravating flushing due to emotional agitation, environmental temperature change or solarization, and may also gradually show persistent erythema or telangiectasia; a few patients are accompanied by pruritus and few patients are also accompanied by psychogenic symptoms such as dysphoria, melancholy, insomnia and the like.
(2) Papulopustular type: some patients can develop papules and pustules on the basis of erythema and telangiectasia, and are mostly seen in the cheek; some patients develop papules and pustules while erythema telangiectasia occurs, and most of them are around the mouth or in the nose.
(3) Hypertrophic type: most of the disease is seen in the nose or around the mouth, and the few disease is seen in the cheek, forehead and ear; hypertrophy of the nose changes the skin lesions known as "nasal tumors".
(4) Eye type: the eye type is few and is often accompanied with the three types; eyelash follicles and related glands of the eyelids, including meibomian glands, sebaceous glands and sweat glands; manifested by subjective symptoms of ocular foreign body sensation, photosensitivity, blurred vision, burning, stinging, dryness or itching.
Clinically, the treatment of the acne rosacea adopts the externally applied azelaic acid cream, brimonidine gel and other medicines, but the medicines have poor treatment effect and are easy to relapse, and the adverse reaction of local stimulation is generated in the using process, so that the skin is damaged; in addition, tacrolimus ointment, metronidazole gel and the like are also used for treating the acne rosacea clinically, but drug resistance and certain toxic and side effects are easy to occur. Therefore, how to treat rosacea safely and effectively remains a problem in the field of dermatology.
Cannabidiol (CAS number: 13956-29-1) is a phyto-cannabinoid derived from industrial cannabis, has anti-inflammatory, immunomodulatory, antioxidant, anti-apoptotic and anti-cancer effects, and has demonstrated therapeutic potential in epilepsy, neurodegenerative diseases, schizophrenia, multiple sclerosis and arthritis. However, the therapeutic effect of cannabidiol on rosacea has not been reported.
Disclosure of Invention
The invention aims to provide a new application of cannabidiol.
The invention provides application of cannabidiol in preparation of a medicine for preventing and/or treating acne rosacea.
Further, the cannabidiol is extracted from cannabis sativa or obtained by organic synthesis.
Furthermore, the purity of the cannabidiol is higher than 98%.
Furthermore, the medicine is used for preventing and/or treating skin erythema.
Further, the above-mentioned drug is a drug for preventing and/or treating skin edema.
Further, the above-mentioned medicament is a medicament for preventing and/or treating telangiectasia.
Further, the above-mentioned drugs are drugs for reducing inflammation.
The invention also provides a medicine for preventing and/or treating skin rosacea, which is a preparation prepared by using cannabidiol as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
Further, the mass fraction of cannabidiol in the preparation is not less than 1%.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
Fig. 1 shows clinical photographs, skin mirror photographs and HE staining results of LL37 in the construction of the rosacea model group and the control group.
Fig. 2 is a clinical photograph of rosacea in each group of mice.
FIG. 3 shows the results of HE staining of mice in each group.
Detailed Description
The starting materials used in the present invention are, unless otherwise stated, known products obtained by purchasing commercially available products.
The cannabidiol is provided by Beijing Taidou Biotechnology Limited, and the purity is more than or equal to 98 percent.
LL37 is an antimicrobial peptide used in the construction of an animal model of rosacea, purchased from shishi biotechnology (shanghai) ltd.
EXAMPLE 1 formulation of pharmaceutical composition for treatment of rosacea
Dissolving cannabidiol in a mixed solution of propylene glycol and 10% dimethyl sulfoxide to prepare a cannabidiol preparation with the mass fraction of 1%.
Experimental example 1 treatment of acne rosacea with cannabidiol
1. Establishment of mouse animal model with rosacea
1.1 BALB/c female mice of 6-7 weeks old are purchased from the experimental animal center of Sichuan university and are fed with special mouse feed and are adapted to the environment for 1 week.
1.2 skin preparation and experimental grouping: 1 day before the experiment, hair with an area of about 4.0cmx2.5cm was removed from the back of BALB/c mice using pet hair clippers and depilatory cream, and the experiment was divided into the following 2 groups: LL-37 group and control group.
1.3 modes of administration and dosages
LL-37 was dissolved in ultrapure water to prepare a 320. mu.M solution of LL-37. After local anesthesia of the mice, the central part of the mouse skin preparation area is selected as an injection area. LL-37 group preparation was injected intradermally with LL-37 solution and control group was injected intradermally with ultrapure water. Injections were given 1 time every 12 hours, 50 μ l each, for a total of 4 times. Observations were made 12 hours after the last injection and mice were sacrificed, direct observations and dermoscopic observations are shown in figure 1. Clear erythema with edema was seen in group LL37, HE further showed intradermal telangiectasia, inflammatory cell infiltration, and no corresponding expression in the control group, indicating successful establishment of the rosacea mouse animal model.
The above results indicate that LL37 can be successfully used to construct a mouse animal model of rosacea.
2. Treatment of acne-like skin lesions with cannabidiol
2.1 BALB/c female mice of 6-7 weeks old are purchased from the experimental animal center of Sichuan university and are fed with special mouse feed and are adapted to the environment for 1 week.
2.2 skin preparation and experimental grouping: 1 day before the experiment, hair was removed in an area of about 4.0cm x2.5cm from the back of BALB/c mice using pet clippers and depilatory cream. The experiments were divided into the following groups of three each: LL37 control (modeled using LL37 only), 1% CBD (treated with the formulation of example 1 with a CBD mass fraction of 1% and modeled with LL 37), matrix (treated with matrix without CBD: propylene glycol + 10% DMSO and modeled with LL 37) and blank control (modeled without LL 37).
2.3 modes of administration and dosages
In the 1% CBD group and the matrix group, 1% CBD and matrix were externally applied to the back of the mice 3 days in advance, 2 times a day, and each dose was 0.1ml/cm2LL37 control and blank control were not treated. After 3 days, the mice were locally anesthetized in the 1% CBD group, the vehicle group, and the LL37 control group, respectively, and the central part of the prepared skin area of the mice was selected as an injection area, and an LL37 solution was injected intradermally at a concentration of 320 μ M1 time per 12 hours and 50 μ l each time for 4 times. In the blank control group, ultrapure water was injected intradermally 1 time every 12 hours and 50. mu.l of ultrapure water was injected 4 times. Observations were made 12 hours after the last injection and mice were sacrificed and HE staining was performed.
As can be seen from fig. 2, LL37 control group: distinct, darker colored erythema with clear borders and obvious symptoms of rosacea. 1% CBD group: pale erythema with unclear borders was observed. Matrix group: erythema comparable to the LL37 control was seen. The blank control group had no significant erythema.
As can be seen in fig. 3, HE staining results for LL37 control group showed visible telangiectasia and more lymphocytic, neutrophil infiltration in the dermis. HE staining results in the 1% CBD group showed no significant vasodilation in the dermis, with only a small amount of lymphocyte infiltration visible. The stroma group showed more lymphocyte and neutrophil infiltration in the dermis. The blank control group had no vasodilation and no significant cellular infiltration.
The results show that cannabidiol can effectively reduce inflammation, improve erythema and edema, reduce telangiectasia and treat acne rosacea.
In conclusion, the invention provides an application of cannabidiol in preparation of a medicine for treating acne rosacea. Cannabidiol can effectively improve erythema and edema of rosacea, improve telangiectasia and reduce inflammation. The medicine for treating the acne rosacea, which takes the cannabidiol as the active ingredient, provides a new choice for clinical application.
Claims (8)
1. Use of cannabidiol in the manufacture of a medicament for the prevention and/or treatment of rosacea.
2. The use of claim 1 wherein the cannabidiol is not less than 98% pure.
3. The use according to claim 1, wherein the medicament is a medicament for the prevention and/or treatment of cutaneous erythema.
4. The use according to claim 1, wherein the medicament is a medicament for the prevention and/or treatment of skin edema.
5. Use according to claim 3 or 4, wherein the medicament is a medicament for the prevention and/or treatment of telangiectasia.
6. The use of claim 1, wherein the medicament is a medicament for reducing inflammation.
7. A medicine for preventing and/or treating skin rosacea is characterized in that the medicine is a preparation prepared by taking cannabidiol as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
8. The medicament of claim 7, wherein cannabidiol is present in the formulation at a weight fraction of no less than 1%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020108508968 | 2020-08-21 | ||
| CN202010850896 | 2020-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114073687A true CN114073687A (en) | 2022-02-22 |
Family
ID=80283389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110969262.9A Pending CN114073687A (en) | 2020-08-21 | 2021-08-23 | Application of cannabidiol in preparation of medicine for preventing and treating acne rosacea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114073687A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109419665A (en) * | 2017-08-25 | 2019-03-05 | 汉义生物科技（北京）有限公司 | A kind of active matter rapid osmotic system containing Cannador or cannabidiol |
| CN110604709A (en) * | 2019-09-21 | 2019-12-24 | 云南辰锦威生物科技有限公司 | Facial mask for moisturizing, repairing and removing acne |
| CN110769819A (en) * | 2017-02-15 | 2020-02-07 | 博塔尼克斯制药有限公司 | Cannabinoid formulations for the treatment of acne |
-
2021
- 2021-08-23 CN CN202110969262.9A patent/CN114073687A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110769819A (en) * | 2017-02-15 | 2020-02-07 | 博塔尼克斯制药有限公司 | Cannabinoid formulations for the treatment of acne |
| CN109419665A (en) * | 2017-08-25 | 2019-03-05 | 汉义生物科技（北京）有限公司 | A kind of active matter rapid osmotic system containing Cannador or cannabidiol |
| CN110604709A (en) * | 2019-09-21 | 2019-12-24 | 云南辰锦威生物科技有限公司 | Facial mask for moisturizing, repairing and removing acne |
Non-Patent Citations (1)
| Title |
|---|
| 李焰梅,郝丹,蒋献.: "《大麻二酚在皮肤科的研究进展》", 《中国皮肤性病学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9750750B2 (en) | Compositions and methods for stimulating hair growth | |
| EP3515420B1 (en) | Pharmaceutical compositions for use in the therapy of blepharitis | |
| US20210113696A1 (en) | Ionic liquid compositions for treatment of rosacea | |
| WO2008150929A1 (en) | Topical compositions comprising a macromolecule and methods of using same | |
| JP2024016022A (en) | Cannabinoid dosing regime for dermatitis and inflammatory skin conditions | |
| CN105209051A (en) | Acne solution | |
| US9278082B2 (en) | Method for treating contact dermatitis | |
| US20060105057A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| CN108283620A (en) | A kind of local medicine composition of inhibitors of phosphodiesterase-4 and preparation method thereof | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| CN104334165B (en) | Pharmaceutical composition for treating inflammation and pain | |
| CN114073687A (en) | Application of cannabidiol in preparation of medicine for preventing and treating acne rosacea | |
| WO2015051763A1 (en) | Icotinib-containing topical skin pharmaceutical composition and use thereof | |
| WO1992003133A1 (en) | Topical treatment of blepharitis | |
| CN102641267A (en) | Externally-applied skin gel as well as preparation method and application thereof | |
| CN116265017A (en) | Pharmaceutical composition comprising benvimod and corticosteroid | |
| CN105853404A (en) | Compound used for treating acne and application thereof | |
| CN104971349A (en) | Externally used compound preparation | |
| US20220387349A1 (en) | Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions | |
| JP2022531154A (en) | Compounds and their use for treating autoimmune skin diseases caused by inflammation | |
| US7863277B1 (en) | Topical antipsychotic composition | |
| US20040022868A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| JP2021510159A (en) | Topical dermatological composition containing cerduratinib and its use | |
| EP2712613A1 (en) | Vitamin K1 and uses thereof | |
| RU2426540C1 (en) | Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220222 |
|
| RJ01 | Rejection of invention patent application after publication |